Journal article
Report of the 14th International Conference on Malignant Lymphoma (ICML) closed workshopon future design of clinical trials in lymphomas
A Stathis, A Iasonos, JF Seymour, C Thieblemont, V Ribrag, E Zucca, A Younes
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018
Abstract
The 14th ICML held in Lugano in June 2017 was preceded by a closed workshop (organized in collaboration with the American Association for Cancer Research and the European School of Oncology) where experts in preclinical and clinical research in lymphomas met to discuss the current drug development landscape focusing on critical open questions that need to be addressed in the future to permit a more efficient drug development paradigm in lymphoma. Topics discussed included both preclinical models that can be used to test new drugs and drug combinations, as well as the optimal design of clinical trials and the endpoints that should be used to facilitate accelerated progress. This report repres..
View full abstractGrants
Funding Acknowledgements
J.F. Seymour reports receiving commercial research grants from Janssen, Celgene, Roche, and Abbvie; reports receiving speakers bureau honoraria from Abbvie and Roche; and is a consultant/advisory board member for Abbvie, Celgene, Janssen, Roche, Sunesis, and Takeda. V. Ribrag is a consultant/advisory board member for Gilead; Infinity; MSD; Bristol, Myers Squibb; Epizyme; Nanostring; Incyte; and Pharmamar. E. Zucca reports receiving speakers bureau honoraria from Gilead, and is a consultant/advisory board member for Roche, Celgene, Abbvie, and Janssen. No potential conflicts of interest were disclosed by the other authors.